News & Videos - TELIX PHARMACEUTICALS LIMITED

MELBOURNE, Australia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET 1 agent, Zircaix® 2 (TLX250-CDx) for the imaging of kidney cancer in the United States (U.S.), subject to regulatory approval. In preparation for a planned commercial rollout, Telix has contracted with...

MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON 1 trial have been published in The Lancet Oncology, reporting that Telix’s first-in-class investigational PET 2 agent, TLX250-CDx (Zircaix® 3 , 89 Zr-girentuximab), is highly accurate in detecting and characterizing clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs). In this...

MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain cancer. TLX101 (4-L-[ 131 I]...

MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara™ 1 , 18 F-floretyrosine or 18 F-FET), an investigational PET 2 agent for the characterization of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients. Given the...

MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology. The updated business model comprises: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech) and Telix Manufacturing Solutions...

Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities PR Newswire MELBOURNE, Australia, Aug. 22, 2024 MELBOURNE, Australia , Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024 . All figures are in AU$ unless otherwise stated. [1] H1 2024 financial highlights Total Group revenue of $364.0 million , an increase of 65% compared to H1...

MELBOURNE, Australia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated. 1 H1 2024 financial highlights Total Group revenue of $364.0 million, an increase of 65% compared to H1 2023, reflecting continued growth in sales of its prostate cancer imaging agent, Illuccix ® in the United States (U.S.), now in its second full year of...

MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara™ 1 , 18 F-floretyrosine or 18 F-FET) an investigational positron emission tomography (PET) agent for imaging progressive or recurrent glioma, following U.S. Food and Drug Administration (FDA) agreement to proceed. Amino acid PET is included in U.S. and European...

Telix Successfully Prices A$650 Million Convertible Bonds PR Newswire MELBOURNE, Australia, July 24, 2024 MELBOURNE, Australia , July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bonds" (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary...

Telix Successfully Prices A$650 Million Convertible Bonds PR Newswire MELBOURNE, Australia, July 24, 2024 MELBOURNE, Australia , July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bonds" (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary...

MELBOURNE, Australia, July 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imaging 1 for prostate cancer. The PDUFA 2 goal date is March 24, 2025. If approved, the new Kit will enable use of a PSMA imaging product with a...

Telix Announces A$600 Million Convertible Bonds Offering PR Newswire MELBOURNE, Australia, July 23, 2024 MELBOURNE, Australia , July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering of A$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary Shares). Managing Director...

Telix Announces A$600 Million Convertible Bonds Offering PR Newswire MELBOURNE, Australia, July 23, 2024 MELBOURNE, Australia , July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering of A$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary Shares). Managing Director...

Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade PR Newswire MELBOURNE, Australia, July 18, 2024 MELBOURNE, Australia , July 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024). Q2 2024 Financial Performance and Guidance Upgrade The Company reports unaudited total revenue of approximately US$124M [1] (AU$189M) primarily...

MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024). Q2 2024 Financial Performance and Guidance Upgrade The Company reports unaudited total revenue of approximately US$124M 1 (AU$189M) primarily generated from sales of Telix’s prostate cancer imaging product Illuccix®. This represents an increase of 55% on the prior...

MELBOURNE, Australia, July 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective Payment System (OPPS) rule to improve payments for diagnostic radiopharmaceuticals 1 for Medicare patients in the United States (U.S.), facilitating continued patient access after transitional pass-through payment status expires. Under the...

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share in Telix. The target size of the Offering is US$200 million in gross proceeds. In addition, Telix expects to grant the Underwriters (as defined below) a 30-day option to purchase up to an...

MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET 1 agent, TLX250-CDx (Zircaix™ 2 , 89 Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC). The rolling BLA submission,...

TLX591 is an investigational anti-PSMA 1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Reported median radiographic progression-free survival (rPFS) is 8.8 months. Builds on prior data from the ProstACT SELECT 2 trial, demonstrating favourable safety profile and biodistribution 3 . MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today...

MELBOURNE, Australia, May 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imaging 1 for prostate cancer. Subject to regulatory approval, this Kit will enable use of a PSMA imaging product with a considerably extended distribution profile...